Sculptor Capital’s AbCellera Biologics ABCL Stock Holding History

Sculptor Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.56M	Buy	+454,000	New	+$2.22M	0.03%	235

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Sculptor Capital's ABCL Position: Q2 2026 in Review

Sculptor Capital opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 454,000 shares worth $3.56M. The stake represents 0.03% of the portfolio and ranks #235 among its holdings.

151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Sculptor Capital held 454,000 shares of AbCellera Biologics worth $3.56M as of Q2 2026.
AbCellera Biologics was a new Sculptor Capital position in Q2 2026.
AbCellera Biologics made up 0.03% of Sculptor Capital's portfolio in Q2 2026, its #235 holding.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Sculptor Capital's 13F filing for Q2 2026, filed 14 Aug 2026.